Rao Sunil V
Duke Clinical Research Institute, Durham, North Carolina, USA.
Rev Cardiovasc Med. 2007;8 Suppl 3:S18-26.
For patients undergoing percutaneous coronary intervention (PCI), bleeding complications are a major clinical concern. With advances in pharmacotherapy and devices over the past 2 decades, the risk of ischemic outcomes, such as myocardial infarction or death, has decreased. Bleeding complications have more recently become a clinical and research priority. Determining the incidence of and risk factors for bleeding is complicated by the multiple systems used to classify bleeding severity and report bleeding events. The origin of the data, clinical trials versus registries, also influences the incidence of reported bleeding events. Registry data suggest that risk of bleeding among patients undergoing PCI is higher in clinical practice than the incidence observed in clinical trials. Another clinical concern is the possible association between PCI-related bleeding complications and myocardial infarction, stroke, or death. Reduction in bleeding risk is a desirable goal that may potentially improve survival and increase comfort for patients undergoing PCI. Using strategies such as careful vascular access, alternative radial artery access, and modified antithrombotic regimen may reduce bleeding during PCI as well as improve patient outcomes.
对于接受经皮冠状动脉介入治疗(PCI)的患者而言,出血并发症是一个主要的临床关注点。在过去20年里,随着药物治疗和器械的进步,诸如心肌梗死或死亡等缺血性结局的风险已经降低。出血并发症最近已成为临床和研究的重点。用于对出血严重程度进行分类和报告出血事件的多种系统使得确定出血的发生率和风险因素变得复杂。数据来源,即临床试验与注册登记,也会影响报告的出血事件发生率。注册登记数据表明,在临床实践中,接受PCI的患者发生出血的风险高于临床试验中观察到的发生率。另一个临床关注点是PCI相关出血并发症与心肌梗死、中风或死亡之间可能存在的关联。降低出血风险是一个理想的目标,这可能会潜在地提高接受PCI患者的生存率并增加其舒适度。采用诸如谨慎的血管通路选择、替代性桡动脉通路以及改良的抗栓方案等策略,可能会减少PCI期间的出血,并改善患者的预后。